Charles Wolfus

Chief Tech/Sci/R&D Officer at ALECTOR, INC.

Health Technology

Consumer Services

Profile

Charles Wolfus is currently the VP-Technology & Digital Health at Alector, Inc. He was previously the Director-Global IT Infrastructure & Operations at Onyx Pharmaceuticals, Inc. from 2011 to 2014 and the VP-Digital Health & Business Operations at MyoKardia, Inc. from 2014 to 2019.
He has an undergraduate degree from the University of California San Diego and a graduate degree from California Western School of Law.

Charles Wolfus active positions

Companies	Position	Start
ALECTOR, INC.	Chief Tech/Sci/R&D Officer	2018-12-31

All active positions of Charles Wolfus

Former positions of Charles Wolfus

Companies	Position	End
MYOKARDIA, INC.	Corporate Officer/Principal	2018-12-31
Onyx Pharmaceuticals, Inc. Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA.	Corporate Officer/Principal	2013-12-31

See the detail of Charles Wolfus's experience

Training of Charles Wolfus

University of California San Diego	Undergraduate Degree
California Western School of Law	Graduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Charles Wolfus's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
ALECTOR, INC.	Health Technology

Private companies	2
Onyx Pharmaceuticals, Inc. Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA.	Health Technology
MyoKardia, Inc. MyoKardia, Inc. Pharmaceuticals: MajorHealth Technology MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA.	Health Technology